LIVE WEBINARS: April 6, May 4, June 2 and July 6, 2021

Ask the Expert: Clinical Investigators Provide Perspectives on the Management of Renal Cell Carcinoma

In Partnership with Project Echo® and Florida Cancer Specialists

Research To Practice in partnership with Project Echo® is pleased to offer four 1-hour CME/MOC-certified virtual sessions. Each program will be moderated by Dr Neil Love and feature a clinical investigator discussing actual cases and the optimal care of patients with renal cell carcinoma (RCC). The program format is conversational, incorporating live, case-based discussions, an investigator-led review of recently published research and ongoing trials, real-time polling of attendees and an opportunity for audience Q&A.

Register Now Submit Your Case

Register for any of these complimentary events with the “Register Now” button above,
which will take you to our Zoom registration page.

Sessions Available on The Following Dates:

Walter Stadler, MD
Fred C Buffett Professor of Medicine
Dean for Clinical Research
Deputy Director, Comprehensive Cancer Center
The University of Chicago
Chicago, Illinois
Wednesday | 5:00 PM – 6:00 PM Eastern Time | Webinar
David I Quinn, MBBS, PhD
Medical Director, USC Norris Cancer Hospital and Clinics
Head, Section of GU Cancer, Division of Oncology
Associate Professor of Medicine
USC Norris Comprehensive Cancer Center
Keck School of Medicine of USC
Los Angeles, California
Tuesday | 5:00 PM – 6:00 PM Eastern Time | Webinar

Project ECHO® collects registration, participation, questions/answers, chat comments, and poll responses for some teleECHO® programs. Your individual data will be kept confidential. These data may be used for reports, maps, communications, surveys, quality assurance, evaluation, research, and to inform new initiatives.

Previous Events

Sumanta K Pal, MD
Clinical Professor, Department of Medical Oncology
City of Hope Comprehensive Cancer Center
Duarte, California
Chung-Han Lee, MD, PhD
Assistant Attending Physician
Genitourinary Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Specific cases selected for discussion during each webinar will be collected from participating general medical oncologists. The outline provide below is intended to illustrate the topics to be covered within each program.

MODULE 1: Current Front-Line Management Strategies for Patients with Advanced Renal Cell Carcinoma (RCC)

Discussion Topics

  • Clinical and biologic factors (eg, risk classification, age, performance status, prior neoadjuvant or adjuvant therapy, number and location of metastases, symptomatology) in the selection of first-line therapy for patients with newly diagnosed metastatic RCC
  • Major efficacy and safety findings from the pivotal Phase III CheckMate 214 trial evaluating nivolumab/ipilimumab versus sunitinib for treatment-naïve advanced RCC
  • Biologic rationale for combining anti-PD-1/PD-L1 antibodies with VEGF-targeted agents for RCC
  • Design, eligibility criteria and key efficacy and safety data from the Phase III KEYNOTE-426 and JAVELIN Renal 101 trials assessing pembrolizumab/axitinib and avelumab/axitinib, respectively, in the front-line setting; optimal integration into current practice
  • Current role of tyrosine kinase inhibitor (TKI) monotherapy in the treatment of newly diagnosed advanced RCC

MODULE 2: Selection and Sequencing of Therapies for Patients with Relapsed/Refractory (R/R) RCC

Discussion Topics

  • Rational sequencing of available therapies for RCC progressing on front-line treatment; patient-specific factors in decision-making (eg, prior systemic therapy, PS, comorbidities)
  • Clinical trial findings with and optimal use of axitinib, cabozantinib and other multikinase inhibitors for patients with R/R RCC
  • Optimal integration of immune checkpoint inhibition into therapy for R/R disease; off-protocol role of approved first-line regimens (eg, nivolumab/ipilimumab, pembrolizumab/axitinib, avelumab/axitinib)
  • Available data with and current clinical role, if any, of immune checkpoint inhibitor rechallenge for patients who have previously experienced disease progression on anti-PD-1/PD-L1 antibody-based regimens
  • Published research data with and optimal integration of lenvatinib/everolimus into management algorithms for R/R RCC
  • Novel agents and strategies with promising activity

MODULE 3: Management of Toxicities and Other Practical Considerations with the Use of Immune Checkpoint Inhibitors and TKIs for Advanced RCC

Discussion Topics

  • Incidence, severity and timing of adverse events associated with commercially available front-line treatment approaches (eg, ipilimumab/nivolumab, pembrolizumab/axitinib, avelumab/axitinib, single-agent TKI)
  • Pathophysiology of common and uncommon adverse events observed with the use of anti-PD-1/PD-L1 antibodies alone or in combination with other immune checkpoint inhibitors or TKIs
  • Recommended algorithms for the management of immune-related adverse events; indications for restarting immune checkpoint inhibitor therapy after resolution of symptoms
  • Optimal duration of immune checkpoint inhibition in RCC
  • Contraindications for immune checkpoint inhibitors in patients with metastatic RCC

Target Audience
These activities have been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of renal cell carcinoma (RCC).

Learning Objectives
At the conclusion of each activity, participants should be able to

  • Effectively apply evidence-based research findings and other clinical and biologic factors in the best-practice selection of first-line therapy for patients with metastatic RCC (mRCC).
  • Recall the underlying research database supporting the FDA approval of anti-PD-1/anti-CTLA-4 combination therapy as first-line treatment for mRCC, and counsel patients regarding the risks and benefits of this novel approach.
  • Appraise available clinical trial data evaluating the use of anti-PD-1/PD-L1 antibody/multikinase inhibitor combinations for previously untreated mRCC, and develop strategies to appropriately integrate these regimens into patient care.
  • Develop a rational approach to the sequencing of systemic therapies for patients with advanced RCC who experience disease progression on first-line treatment, incorporating multikinase inhibitors, mTOR inhibitors, immunotherapeutic agents and other approaches.
  • Recognize side effects and toxicities commonly associated with approved therapeutic approaches to RCC, and use this information to develop supportive care plans for patients undergoing treatment.
  • Recall available and emerging data with other investigational agents and strategies currently in testing for RCC, and where applicable, refer eligible patients for clinical trial participation.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Pal has no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr LeeConsulting Agreements: Bristol-Myers Squibb Company, Eisai Inc, EMD Serono Inc, Exelixis Inc, Merck, Pfizer Inc; Contracted Research: Bristol-Myers Squibb Company, Calithera Biosciences, Eisai Inc, Exelixis Inc, Lilly, Merck, Pfizer Inc. Dr QuinnAdvisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Merck, Pfizer Inc: Data and Safety Monitoring Board/Committee: Eisai Inc. Dr StadlerAdvisory Committee: Caremark, Genentech, a member of the Roche Group, Pfizer Inc; Consulting Agreement: Actavis LLC; Contracted Research: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Clovis Oncology, Corvus Pharmaceuticals, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Johnson & Johnson Pharmaceuticals, Merck, Novartis, Pfizer Inc, Seagen Inc, Tesaro, A GSK Company, X4 Pharmaceuticals; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Merck, Pfizer Inc, SOTIO LLC, Treadwell Therapeutics.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These activities are supported by an educational grant from Pfizer Inc.